Dyslipidemia in CKD is also characterized by elevated levels of apolipoprotein C-III (apoC-III), an exchangeable apolipoprotein on lipoprotein particles that inhibits lipoprotein lipase, thereby reducing clearance of very-low-density-lipoproteins (VLDL) and the triglycerides (TGs) they carry [2, 9–18]. Here, APOC3 is linked to chronic kidney disease.